New Zealand markets closed

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
47.07-0.62 (-1.30%)
At close: 04:00PM EST
47.51 +0.44 (+0.93%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous close47.69
Open47.44
Bid47.00 x 1400
Ask47.51 x 1000
Day's range46.92 - 47.53
52-week range45.17 - 54.26
Volume1,941,080
Avg. volume1,804,412
Market cap118.877B
Beta (5Y monthly)0.43
PE ratio (TTM)16.98
EPS (TTM)2.77
Earnings dateN/A
Forward dividend & yield1.93 (4.04%)
Ex-dividend date03 May 2021
1y target est64.63
  • GlobeNewswire

    Sanofi: Information concerning the total number of voting rights and shares - October 2021

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,526,866,030 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under n

  • GlobeNewswire

    Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates

    Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates Sanofi confirms Vaccines mid-term guidance of mid-to-high single-digit sales growth1, ambition to more than double Vaccines sales by the end of the decade2Broad pipeline of innovative vaccines, with a total of 10 candidates planned to advance into the clinic by 2025, six of which will leverage the recently established mRNA Center of ExcellenceHybrid Vaccines Inve

  • GlobeNewswire

    Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy

    Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy Origimm brings expertise in antigen discovery for immune modulation of skin microbiome-associated disordersTransaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwideSanofi to leverage its next-generation mRNA platform to unlock potential of vaccine-candidate PARIS and VIENNA – December 1, 2021 – Sanofi anno